Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19162069&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Role of voltage-gated calcium channels in ascending pain pathways Zamponi GW; Lewis RJ; Todorovic SM; Arneric SP; Snutch TPBrain Res Rev 2009[Apr]; 60 (1): 84-9Voltage gated calcium channels (VGCCs) are well established mediators of pain signals in primary afferent neurons. N-type calcium channels are localized to synaptic nerve terminals in laminae 1 and 2 of the dorsal horn where their opening results in the release of neurotransmitters such as glutamate and substance P. The contribution of N-type channels to the processing of pain signals is regulated by alternate splicing of the N-type channel gene, with unique N-type channel splice variants being expressed in small nociceptive neurons. In contrast, T-type VGCCs of the Ca(v)3.2 subtype are likely localized to nerve endings where they regulate cellular excitability. Consequently, inhibition of N-type and Ca(v)3.2 T-type VGCCs has the propensity to mediate analgesia. T-type channel activity is regulated by redox modulation, and can be inhibited by a novel class of small organic blockers. N-type VGCC activity can be potently inhibited by highly selective peptide toxins that are delivered intrathecally, and the search for small organic blockers with clinical efficacy is ongoing. Here, we provide a brief overview of recent advances in this area, as presented at the Spring Pain Research conference (Grand Cayman, 2008).|Afferent Pathways/drug effects/*metabolism/physiopathology[MESH]|Analgesics/chemistry/pharmacology[MESH]|Animals[MESH]|Calcium Channels/drug effects/genetics/*metabolism[MESH]|Ganglia, Spinal/drug effects/metabolism/physiopathology[MESH]|Humans[MESH]|Ion Channel Gating/drug effects/physiology[MESH]|Nervous System/drug effects/*metabolism/physiopathology[MESH]|Nociceptors/drug effects/*metabolism[MESH]|Pain/drug therapy/*metabolism/physiopathology[MESH]|Posterior Horn Cells/drug effects/metabolism/physiopathology[MESH]|Sensory Receptor Cells/drug effects/*metabolism[MESH] |
